On November 11, 2026, Reuters reported a number that reframed how pharmaceutical companies reach physicians in China. Alibaba Health had surveyed several hundred doctors. 93 percent said they used AI tools in their clinical work, up from roughly 70 percent a year earlier.

The same reporting described what pharmaceutical companies were doing about it. After a sweeping anti-graft crackdown made traditional hospital visits and academic events harder to arrange, drugmakers were shifting marketing budgets toward the AI platforms where doctors were already spending their time. Alibaba Health's Chief Technology Officer Wang Xiangzhi told Reuters that the company was exploring a model in which promoted clinical research and medical evidence would appear alongside relevant machine-generated answers on its Hydrion app, much like the advertising model that funds OpenEvidence in the United States. Both domestic and foreign drugmakers were, in his words, "very, very" interested. Alibaba Health has not yet begun collaborating with drugmakers on Hydrion.

The commercial logic is not subtle. If the doctors are on the platform, the marketing budgets will follow. Frost & Sullivan estimates that total enterprise spending on digital health marketing in China — the world's second-largest pharmaceutical market — will grow at a compound annual rate of 27.5 percent from 2027 to 2030, reaching 274.4 billion yuan ($41.1 billion). The research firm does not break out spending specifically on physician-facing AI apps, because that category did not exist in a meaningful commercial form until this year.

What exists now is a new channel: a place where doctors go to look up clinical evidence, and where drugmakers are willing to pay to be part of the answer.

Why the Budgets Moved

The shift did not begin with the technology. It began with enforcement.

China's anti-graft campaign in the healthcare sector intensified through 2025 and 2026, with heightened scrutiny of hospital visits by sales representatives, academic conferences sponsored by drugmakers, and the informal relationships that had long lubricated pharmaceutical marketing. Reuters reported that the crackdown "disrupted traditional engagement channels" and "hurt sales," with at least one listed Chinese drugmaker reporting a direct hit to sales after stricter measures on sales representatives disrupted academic events.

The traditional model was relationship-based. A sales representative visited a doctor, left educational materials, perhaps sponsored a conference, and built a rapport that translated into prescriptions. When the visits stopped and the conferences came under scrutiny, the channel did not disappear. It moved.

Doctors were already moving to AI. The 93 percent figure measures usage, not experimentation. The doctors Alibaba Health surveyed were not trying a novelty. They were using AI tools to look up clinical guidelines, compare treatment options, and parse medical literature — the same kind of information that sales representatives and sponsored conferences had once provided, but faster and on demand.

The AI platform became the place where the doctor's attention already was. The drugmaker's budget followed the attention.

How the Platforms Monetize the Attention

The model Alibaba Health is considering is the most explicit.

The Hydrion app, according to Reuters, would allow promoted medical research and clinical evidence to appear alongside machine-generated responses to physician questions. Wang framed it as a way to connect drugmakers with doctors who are actively seeking clinical information: if doctors are gathered on a single platform, and pharmaceutical companies can promote evidence supporting their products, the marketing budgets that once funded hospital visits would move online.

The interest is already there. Roche said it was exploring the use of third-party medical AI tools to reach doctors and hospitals. Bayer said it continuously monitors developments. Both statements are cautious, but both acknowledge the channel.

The model is not limited to Alibaba Health. PICA Health, a medical education firm, incorporated JD Health's AI-powered Zhiyi assistant into its app, and said in August 2026 that the partnership would provide drugmakers with "targeted, grassroots-level digital academic promotion and physician education services." The emphasis on "grassroots-level" is significant. The doctors who most need clinical evidence — those in county hospitals and primary care clinics, far from academic medical centers — are exactly the audience that AI platforms can reach at low marginal cost and that traditional sales forces struggled to cover efficiently.

Yidu Tech has also held discussions with drugmakers about marketing on its Yidu Evidence app, according to a company executive who spoke to Reuters on condition of anonymity. The executive described the drugmakers' interest directly: "They hope to have more academic endorsements, to be ranked higher in searches." Yidu Tech was not yet offering that functionality at the time of the report, but the demand signal was clear. Drugmakers were not asking whether they could pay for placement. They were asking how.

The pattern is consistent across platforms. The AI assistant becomes the doctor's entry point for clinical information. The platform controls the ranking and presentation of that information. The drugmaker pays for visibility within the answer. The budget that once funded a sales representative's train ticket now funds a promoted clinical trial summary.

The Compliance Argument

The platforms and the drugmakers are making a specific argument about why this model is not the same as the practices the crackdown targeted.

The argument is that promoting clinical evidence is different from promoting a drug through gifts, meals, or sponsored travel. A doctor who sees a summary of a peer-reviewed trial while looking up a treatment question is receiving medical information, not a bribe. The platform can present the evidence with citations, link to the full study, and label it as sponsored content. The doctor can evaluate the evidence on its merits.

Wang made a version of this argument to Reuters: the budgets currently spent on traditional marketing would move online, where they could support clinical evidence rather than relationship-building. The framing is that the AI platform makes pharmaceutical marketing more evidence-based, not less.

There is a plausible case for that. A county-hospital doctor who cannot afford journal subscriptions and does not have time to search PubMed may benefit from a curated summary of relevant trials, even if the curation is sponsored. The information is real; the sponsorship is disclosed; the doctor makes the final judgment.

But the compliance argument has a limit. It addresses the content of the promotion — clinical evidence is better than gifts — but it does not address the structure of the attention market. A platform that ranks evidence by sponsorship still shapes what the doctor sees. The fact that the shaped content is a clinical trial rather than a dinner invitation changes the input, not the shaping.

The American Precedent and the Ethical Question

The model is not uniquely Chinese. OpenEvidence, the American physician-facing AI platform, provides free medical question-answering to doctors and generates revenue from pharmaceutical and medical-device advertising. A JAMA study published in October 2026 found that more than 950,000 U.S. clinicians had used OpenEvidence over a 2.5-year period, submitting approximately 271 million queries. The study reported that a substantial share of those queries involved clinical decision-making, particularly treatment and patient management, according to the JAMA analysis.

OpenEvidence says its advertising system and its AI answer generation are independent. The company has stated that ads do not influence the answers. But a separate JAMA article in June 2026 examined the ethical risk: when a doctor is comparing treatment options and the AI presents relevant evidence alongside a sponsored study, the ad may draw attention to one drug even if it does not change the answer. The article's authors argued that platforms need to clearly label advertising and continuously demonstrate the independence of medical information, beyond simply keeping the ad system separate from the model.

The Chinese platforms will face the same question. The compliance argument — "it's clinical evidence, not a gift" — is necessary but not sufficient. The harder question is whether a doctor can distinguish the evidence the AI selected because it was relevant from the evidence it surfaced because someone paid for it to be surfaced. If the distinction is not clear, the platform has replaced one form of influence with another, more subtle form.

What the 93 Percent Actually Means for Pharma

The 93 percent figure is not a marketing statistic. It is a description of where clinical attention has moved.

Doctors in China are using AI tools at a scale that no other professional group in the country has matched. They are using them for clinical information, not for entertainment or experimentation. That usage creates a concentrated point of attention that did not exist before the AI platforms launched. The pharmaceutical industry is responding to that concentration because the alternative — the traditional sales force — has been constrained by enforcement.

The platforms are positioning themselves as the compliant alternative. The drugmakers are positioning their spending as evidence-based promotion. The doctors are using the tools because they are useful. Each of those positions is defensible on its own terms.

The unresolved question is what happens when the three positions interact. A doctor looks up a treatment. The AI generates an answer. A sponsored trial appears alongside it. The doctor prescribes. Was the prescription based on the evidence, or on the placement of the evidence? The platform says the two systems are separate. The regulator will want to see the audit trail. The doctor will want to believe they were not influenced.

None of those parties is acting in bad faith. The market is forming around a real need and a real constraint. The 93 percent measures how far the doctors have already moved. The 274 billion yuan measures how much money is following them.

Sources: Reuters via Investing.com (November 11, 2026); Reuters via Economic Times (November 11, 2026); Pharma Economic Times (November 12, 2026); IUX24 (November 11, 2026); Sohu Health (November 13, 2026); Frost & Sullivan estimates via Reuters (November 11, 2026) and IUX24 (November 11, 2026); JAMA study on OpenEvidence clinician usage (October 15, 2026); JAMA article on medical AI advertising ethics (June 2026); CMoney on JD Health's Zhiyi assistant and PICA Health (November 2026); OR100 on Roche and Bayer statements (November 2026).

Disclaimer

The information provided in this article is for general informational and educational purposes only. It does not constitute legal, financial, or professional advice. The author and publisher are not responsible for any actions taken based on the content of this article. Readers should consult qualified professionals for advice specific to their situation. All trademarks and references to third-party products, services, or organizations are the property of their respective owners. The performance data and benchmarks discussed are based on specific research studies and may not generalize to all use cases or environments. As of the publication date, the AI landscape continues to evolve rapidly, and readers should verify current information independently.

Limitations

The 93% figure comes from an Alibaba Health survey of several hundred doctors; the sampling method was not disclosed.

The 274.4 billion yuan projection is a Frost & Sullivan forecast for digital health marketing overall, not for physician-facing AI apps.

Platform revenue figures are company statements and analyst estimates, not audited segment reporting.

Physician adoption surveys in China are not independently replicated, and self-reported usage may overstate clinical reliance.

Reporting standards and disclosure requirements differ between Chinese and U.S. sources, so figures are not always directly comparable.

Market size and forecast estimates come from research firms whose methodologies vary; treat them as directional.

The sectors discussed are changing quickly, and readers should verify current figures independently.


Sources

  1. Reuters via Investing.com (November 11, 2026)
  2. Reuters via Economic Times (November 11, 2026)
  3. Pharma Economic Times (November 12, 2026)
  4. IUX24 (November 11, 2026)
  5. Sohu Health (November 13, 2026)
  6. Frost & Sullivan estimates via Reuters (November 11, 2026) and IUX24 (November 11, 2026)
  7. JAMA study on OpenEvidence clinician usage (October 15, 2026)
  8. JAMA article on medical AI advertising ethics (June 2026)
  9. CMoney on JD Health's Zhiyi assistant and PICA Health (November 2026)
  10. OR100 on Roche and Bayer statements (November 2026).

The information provided in this article is for general informational and educational purposes only. It does not constitute legal, financial, or professional advice. The author and publisher are not responsible for any actions taken based on the content of this article. Readers should consult qualified professionals for advice specific to their situation. All trademarks and references to third-party products, services, or organizations are the property of their respective owners. The performance data and benchmarks discussed are based on specific research studies and may not generalize to all use cases or environments. As of the publication date, the AI landscape continues to evolve rapidly, and readers should verify current information independently.

Limitations: The 93% figure comes from an Alibaba Health survey of several hundred doctors; the sampling method was not disclosed.; The 274.4 billion yuan projection is a Frost & Sullivan forecast for digital health marketing overall, not for physician-facing AI apps.; Platform revenue figures are company statements and analyst estimates, not audited segment reporting.; Physician adoption surveys in China are not independently replicated, and self-reported usage may overstate clinical reliance.; Reporting standards and disclosure requirements differ between Chinese and U.S. sources, so figures are not always directly comparable.; Market size and forecast estimates come from research firms whose methodologies vary; treat them as directional.; The sectors discussed are changing quickly, and readers should verify current figures independently.